Imaging and Hepatology

Jacob Sosna, MD


Department of Radiology
Hadassah-Hebrew University Medical Center
Jerusalem, Israel



The Invention of Computed Tomography



Allan M. Cormack



Godfrey N. Hounsfield

Nobel Prize in Physiology and Medicine, 1979


























The Invention of Magnetic Resonance Imaging


Nobel Prize in Physiology or Medicine, 2003



MRI









From Structure to Function

Anatomical Imaging

US

X-ray

CT

MRI

System Functional Imaging

PET – Blood flow, radioactively tagged water


fMRI – Blood flow, intrinsic contrast, Blood volume, injected

contrast agents, biologically inert

US - Perfusion, ultrasound contrast agents



CEUS




Baseline

Early arterial phase

Peak arterial phase



PET/MR






Imaging Principles

- Dual blood supply
- Changes in blood flow in diseased liver
- Contrast between lesion and background
- Diffuse vs. focal pathology







Nodular HCC Tumour HCC vessels Portal vein ■Hepatic artery Antegrade flow in portal vein



CT Technique


- Contrast 60-180 cc/sec (40 grl)
- Rate 3-6 cc/sec
- Timing
- Thin slices (0.625-1.5 mm)
- Overlap enables reconstructions



CT Technique

- Non enhanced
- Early arterial
 - (for vessel demonstration): 25 sec
- Late arterial
 - (hypervascular masses):35 sec
- Portal phase
 - 70 sec
- Delayed
 - 3 min in HCC
 - 10 minutes for Cholangiocarcinoma






MR Imaging


- T1
- T2
- Diffusion
- Gadolinium injection
- Liver specific agents
- Dynamic series
 - » Late arterial, portovenous, delayed (3, 10 min)








Assessment of Vascularity:



- Arterial heterogeneous enhancement
- Portal phase- wash-out
- "Pseudocapsule"
- Equilibrium phase-further washout



Assessment of tumor cellularity: Diffusion-weighted imaging (DWI)





Multi-step Approach

- Underlying liver
- Portal hypertension
- Lesion/s
- Pitfalls and mimickers



Target Lesion Evaluation

- Size
- Location
- Possibility of resection, RF, Chemoembolization



State of the Art

- Imaging: gets better all the time!
- Visualization: commercial
- Multimodality registration: progressing fast. BUT...

Still a wide gap between what is developed in the research lab and what goes into commercial systems



Enjoy This Conference



